Physician profile
Kent Blakely
NPI 1134222458
$6,456.79
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,415 · 2020: $319 · 2021: $2,118 · 2022: $1,918 · 2023: $479 · 2024: $208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $582 · Education: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $582.15 |
| Education | $104.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,160.97 | 2019-2024 | Tavneos, Evenity, Otezla |
| Abbvie INC. | $1,125.95 | 2019-2023 | Rinvoq, Humira |
| Astrazeneca Pharmaceuticals Lp | $646.31 | 2021-2022 | |
| Janssen Biotech, INC. | $483.60 | 2021-2023 | Tremfya |
| Horizon Therapeutics Plc | $323.08 | 2021-2023 | Krystexxa |
| Ucb, INC. | $238.99 | 2021-2022 | |
| Glaxosmithkline, LLC. | $226.09 | 2019-2024 | Benlysta |
| Radius Health, INC. | $182.18 | 2019-2022 | |
| Pfizer INC. | $151.53 | 2019-2023 | |
| Genzyme Corporation | $145.04 | 2019 | |
| Novartis Pharmaceuticals Corporation | $120.42 | 2019-2024 | |
| Alexion Pharmaceuticals, INC. | $111.18 | 2019-2024 | Strensiq |
| Aurinia Pharma U.S., INC. | $100.00 | 2021 | |
| Lilly USA, LLC | $97.92 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $97.68 | 2021-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $55.83 | 2019-2022 | |
| Daiichi Sankyo INC. | $48.74 | 2023-2024 | Injectafer |
| Celgene Corporation | $31.15 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.76 | 2019 | |
| Mallinckrodt Enterprises LLC | $24.12 | 2019 | |
| Hikma Pharmaceuticals USA | $19.66 | 2019 | |
| Alfasigma USA, INC. | $18.98 | 2021 | |
| Sun Pharmaceutical Industries INC. | $16.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kent Blakely listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.